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Abstract: Increasing the clinical efficacy of toxic chemotherapy drugs such as cisplatin 
(CDDP), via targeted drug delivery, is a key area of research in cancer treatment. In this study, 
CDDP-loaded poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles (NPs) were suc-
cessfully prepared using electrohydrodynamic atomization (EHDA). The configuration was 
varied to control the distribution of CDDP within the particles, and high encapsulation efficiency 
(.70%) of the drug was achieved. NPs were produced with either a core–shell (CS) or a matrix 
(uniform) structure. It was shown that CS NPs had the most sustained release of the 2 formula-
tions, demonstrating a slower linear release post initial “burst” and longer duration. The role of 
particle architecture on the rate of drug release in vitro was confirmed by fitting the experimental 
data with various kinetic models. This indicated that the release process was a simple diffusion 
mechanism. The CS NPs were effectively internalized into the endolysosomal compartments 
of cancer cells and demonstrated an increased cytotoxic efficacy (concentration of a drug that 
gives half maximal response [EC
50
] reaching 6.2 µM) compared to free drug (EC
50
 =9 µM) and 
uniform CDDP-distributed NPs (EC
50
 =7.6 µM) in vitro. Thus, these experiments indicate that 
engineering the structure of PLGA NPs can be exploited to control both the dosage and the 
release characteristics for improved clinical chemotherapy treatment.
Keywords: cisplatin, drug delivery, cancer chemotherapy, polymer, poly(lactic-co-glycolic 
acid), nanoparticles, electrohydrodynamic atomization, controlled release
Introduction
Platinum-based compounds such as cisplatin (CDDP) constitute one of the most widely 
used group of chemotherapeutic agents,1,2 employed in ~50% of cancer treatments.3 In 
a complex process, CDDP causes unrepairable platinum–DNA adducts leading to suf-
ficient DNA damage to trigger cell apoptosis and has been shown to be highly effective in 
the treatment of many malignancies, including testicular, ovarian, cervical, and head and 
neck cancers. However, its systemic toxicity means its clinical use is dose limited, and 
hence, its therapeutic effect in many applications is restricted.4 Therefore, the develop-
ment of a controlled release drug delivery system for CDDP represents a key challenge 
in achieving optimum clinical response for this potent chemotherapy agent.5 
In recent years, the continued search for effective cancer treatment has led to 
the emergence of many nanosized vectors for the delivery of chemotherapeutics, 
for example, liposomes6 and polymeric particles,7,8 which aim to reduce premature 
interaction with the biological environment and improve cellular targeting.9,10 Impor-
tantly, the physicochemical properties of nanovectors influence their efficacy as drug 
delivery systems. Therefore, this structure–activity relationship can be harnessed to 
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engineer nanomaterials as chemotherapeutic delivery agents 
for improved antitumor efficacy. It has been reported that 
controlling the size of particles can enable them to penetrate 
tissue structures.11 Furthermore, the structure of nanovectors 
strongly influences their stability and drug delivery profile. 
It has been shown in vitro that core–shell (CS) structures 
can control the release of drugs, suggesting that they have 
great potential as drug delivery systems.12,13 Additionally, CS 
structuring can enhance the thermal and chemical stability 
of nanoparticles (NPs) and reduce cytotoxicity.14
Polymeric nanosized carriers, particularly poly(lactic-
co-glycolic acid) (PLGA), have been extensively reported 
as nanovectors due to favorable biodegradability and 
biocompatibility properties.15 Encapsulation of CDDP into 
polymeric NPs is a considerable challenge on account of its 
physicochemical properties, in particular, its poor solubil-
ity in organic solvents.16,17 Recently, electrohydrodynamic 
atomization (EHDA) has been utilized to successfully 
encapsulate both hydrophobic and hydrophilic drugs within 
polymeric carriers, achieving high encapsulation efficiency 
and exhibiting excellent control over particle size and 
distribution.18–21 Additionally, drug encapsulation using 
EHDA is a single-step procedure requiring no subsequent 
processing steps to remove solvents or templating agents, in 
effect producing delivery agents that can be directly utilized 
in vivo without further pretreatment.22 Importantly, of the 
various electro-encapsulation processes that have been inves-
tigated, coaxial EHDA processing holds immense potential 
for producing nanovector CS structures that may reduce 
any burst release characteristics and achieve near zero-order 
release kinetics.19,23
Therefore, this study aims to investigate the relationship 
between NP structure and antitumor efficacy to develop 
CDDP-loaded PLGA particles for enhanced cancer therapy. 
EHDA was utilized in single and coaxial configurations to 
form CDDP-loaded particles with varying internal structure 
(from uniform matrix to CS). The characteristics of the 
CDDP-loaded NPs were investigated systematically. First, 
the influence of NP structure on the delivery profile and cel-
lular uptake was studied in vitro. Second, anticancer efficacy 
was examined.
Methods
Materials
PLGA (copolymer 50:50, Resomer RG503H, molecular 
weight of 33,000 Da, inherent viscosity 0.41 dL g−1) was 
obtained from Boehringer Ingelheim (Ingelheim, Germany). 
Dimethylacetamide (DMAc) and rhodamine B (RhB) were 
obtained from Sigma-Aldrich (Poole, UK). CDDP, molecular 
weight of 300 g mol−1) was purchased from Enzo Life 
Sciences (Exeter, UK).
Particle fabrication
For single-needle electrospraying experiments, PLGA 
solutions (2 wt%) were prepared by dissolving the polymer in 
DMAc and mechanically stirring for 400 s. CDDP (2 mg/mL) 
was added to one of the solutions (for production of drug-
loaded particles) followed by stirring for a further 500 s in 
ambient temperature (20°C) to ensure the total dissolution of 
both the drug and the polymer. In a separate study, 0.005 wt% 
RhB was added to both solutions (with and without CDDP) 
to evaluate uptake of the NPs into tumor cells.
In order to prepare CS particles with the coaxial configu-
ration, 2 mg/mL of CDDP was dissolved in DMAc as the 
inner (core) solution. PLGA (2 wt%) was dissolved in the 
same solvent (DMAc) to prepare the outer (shell) solution. 
For the purpose of the cell uptake studies, an additional 
solution containing 0.005 wt% RhB and 2 wt% PLGA was 
prepared to label the outer shell of the particles prepared with 
the coaxial configuration.
The solutions were electrosprayed using both single-
needle EHDA and coaxial setups (Figure S1) to produce 
particles. In the single-needle configuration, the solu-
tions were made to flow through a stainless steel needle 
(18 G, inner diameter [ID]: 0.84 mm and outer diameter 
[OD]: 1.27 mm) via a syringe pump (PHD 4400; Harvard 
Apparatus Limited, Edenbridge, UK) at a constant flow rate 
of 2.5, 3, 4, or 5 µL/min. For the coaxial configuration, the 
inner drug and outer polymer solutions were fed through 
coaxial stainless steel needles of 19 G (ID: 0.69 mm and 
OD: 1.07 mm) and 16 G, (ID: 1.2 mm and OD: 1.6 mm), 
respectively. The flow rates adjusted for these solutions in 
order to achieve a stable cone jet were 2 and 4 µL/min for 
inner and outer solutions, respectively. A high precision 
voltage supply (Glassman Europe Ltd, Bramley, UK) was 
used to apply an electric potential difference between the 
needle and a ground electrode to the solution and was varied 
from 12 to 20 kV as required to form a stable cone jet. The 
particles were collected at a working distance of 200 mm 
below the device exit directly on to glass slides or aluminum 
foil, respectively, for characterization and measurement of 
drug release. The jet and particle formation processes were 
monitored using a Leica DMS300 camera (Leica Microsys-
tems, Wetzlar, Germany). Experiments were conducted at 
the ambient temperature of 19°C–21°C and relative humid-
ity of 40%–50%. Each experiment was conducted at least 
3 times to ensure the reproducibility of the EHDA process 
and consistency of the particles produced.
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Particle characterization
Optical microscopy and scanning electron 
microscopy
Samples of particles were collected on glass slides. These 
were analyzed initially under an optical microscope (Eclipse 
ME 600; Nikon, Tokyo, Japan) fitted with a camera (Micro-
publisher 3.3 RTV, 3.3 megapixel CCD Color-Bayer Mosaic, 
Real Time Viewing camera; Media Cybernetics, Marlow, 
UK). Further analysis of particle size and morphology 
was carried out using a field emission scanning electron 
microscope (SEM; XL30 FEG; Philips, Amsterdam, the 
Netherlands). Both optical (bright-field) and scanning elec-
tron micrographs were analyzed using ImageJ to determine 
the average diameter and standard deviation of the popula-
tion of particles (300 particles were measured from each 
sample). An INCA X-sight EDAX system (Oxford Instru-
ments, Abingdon, UK) was used with the XL30 microscope 
for energy dispersive X-ray (EDX) spectroscopy analysis to 
identify the presence of CDDP in the NPs.
Fourier transform infrared spectroscopy
The infrared spectra of CDDP, PLGA NPs, and drug-loaded 
NPs were recorded using a Fourier Transform Infrared 
(FTIR-ATR-Perkin Elmer 2000, PerkinElmer, Waltham, 
MA, USA) spectrophotometer. Spectra of all materials 
were recorded using a frequency range of 400–4,000 cm−1 
and averaged over 4 runs. Powdered samples were placed 
on the attenuated total reflectance (ATR) crystal and then 
compressed using an axial screw.
Transmission electron microscopy
The structural characteristics of the NP formulations and 
CDDP distribution within them were examined using a 
transmission electron microscope (TEM; CM12; Philips) 
and EDX analysis (JEM-2100 – Jeol TEM fitted with X-max 
EDAX system – Oxford Instruments). For this part of the 
work, particles were sprayed directly on to carbon-coated 
copper grids and analyzed without additional contrast.
In vitro drug release
Following a previously published protocol,24 20 mg of CDDP-
loaded NPs were dispersed in 1.5 mL of phosphate-buffered 
saline (PBS) (pH 7.4) and incubated at 37°C. At prede-
termined time intervals, the dispersion was centrifuged 
(14,000 rpm), and then 0.5 mL aliquots of solution were 
removed for the purpose of measurement and replaced with 
fresh buffer solution. Aliquots of the supernatant were cen-
trifuged and analyzed using a VP Series High Performance 
Liquid Chromatography (HPLC) system (Shimadzu, 
Kyoto, Japan). Liquid chromatography was optimized on 
a 250×4.6 mm diameter Hypersil GOLD SAX column 
(ThermoFisher Scientific, Waltham, MA, USA) under iso-
cratic conditions using a UV/VIS photodiode array detector 
(Shimadzu). A mobile phase of NaCl solution (0.9% w/v) 
and methanol (95:5) was used at a flow rate of 0.7 mL/min. 
A calibration plot to calculate the CDDP concentrations of 
unknown measurements was produced by measuring the 
absorbance of different concentrations of CDDP solution 
(0.9% w/v saline) from 1 to 50 µg/mL.
In order to determine the encapsulation efficiency of 
CDDP, 10 mg of CDDP-loaded nano/microparticles were 
mixed with DMAc followed by addition of PBS. The solu-
tion was then passed through a 0.22 µm filter and analyzed 
by reverse-phase HPLC method (refer “In vitro drug release” 
section). Encapsulation efficiency (percentage of the amount 
of drug added initially that was entrapped in the NPs) was 
calculated using the formula:
 Encapsulation efficiency EE Wt Wi( %) %= ×100  (1)
where Wt is the actual drug loading and Wi is the weight of 
drug used in particle synthesis.
The NonlinearModelFit function within Mathematica 
(Wolfram Research, Champaign, IL, USA) was used to fit 
the release rates of uniform and CS CDDP-loaded PLGA 
particles. Quality of fit was assessed using the adjusted R2 
parameter (the adjustment allows for different numbers of 
fitting parameters).
In vitro cell cytotoxicity assays
Cell viability was determined in a human head and neck 
squamous carcinoma cell line (UM-SCC-47) obtained from 
Dr Thomas Carey, University of Michigan. All the UM-SCC 
cell lines were established from head and neck cancer patients 
who gave written informed consent in studies reviewed and 
approved by the University of Michigan Medical School 
Institutional Review Board and by the UCL Cancer Institute 
for their use in this study. UM-SCC-47 cells were grown 
in Roswell Park Memorial Institute (RPMI)-1640 medium 
supplemented with 10% fetal bovine serum (FBS).
For the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe - 
nyltetrazolium bromide (MTT) assay (Sigma-Aldrich, St. 
Louis, MO, USA), cultured UM-SCC-47 cells were seeded 
into 96-well flat-bottomed plates at a density of 5×103 cells 
in 100 µL of medium and incubated for 24 h in a 5% CO
2
 
atmosphere at 37°C. They were then incubated in growth 
medium containing different concentrations of CDDP or 
equivalent CDDP-loaded PLGA NPs for 24, 48, or 72 h. 
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Media containing different CDDP dosages were made up 
from successive dilutions in warmed media, from a stock 
solution of CDDP in sterile PBS (1 mM). After treatment, 
MTT (5 mg/mL in PBS) was diluted 1:100 with medium 
into each well. After 2 h of incubation, culture supernatants 
were aspirated, and purple insoluble MTT product was dis-
solved in 100 µL of dimethyl sulfoxide (DMSO)/ethanol 
(EtOH) (50:50) for 10 min. The absorbance in each well 
was recorded at 570 nm using a microplate reader; blanks 
were subtracted from all data, and the results were analyzed 
using Origin software (OriginLab, Northampton, MA, USA). 
Viability was presented as the percentage of the absorbance 
of CDDP-treated cells to the absorbance of nontreated cells 
as a function of CDDP concentration.
In the live/dead assay, UM-SCC-47 cells were seeded 
on glass coverslips in 24-well plates, 50,000 cells per well. 
When cells reached 70% confluency, they were treated with 
growth medium containing different concentrations of CDDP 
or equivalent CDDP-loaded PLGA NPs for 24, 48, or 72 h. 
Live and dead cells were then separately stained. Briefly, 
each well was washed with PBS twice before 1 mL of 2 µM 
calcein AM (ThermoFisher Scientific) and 4 µM ethidium 
homodimer-1 (ThermoFisher Scientific) working solution 
was added to each well and incubated for 40 min at ambient 
temperature. Finally, each coverslip was mounted on a glass 
slide and viewed by confocal microscopy (radiance 2100 laser 
scanning confocal microscope; Bio-Rad, Hercules, CA, USA) 
attached to a BX51 microscope (Olympus, Tokyo, Japan).
Fluorescence-activated cell sorting 
analysis for apoptosis
Cells were grown in 24-well plates incubated in the pres-
ence of CDDP-loaded PLGA NP or free CDDP at 37°C for 
24, 48, and 72 h. After the treatment period, the cells were 
removed and washed thrice with PBS. The cells were then 
treated with annexin-V (Invitrogen, Carlsbad, CA, USA), 
a marker of apoptosis and incubated in the dark, at ambient 
temperature, for 15 min. The cells were then washed with 
PBS and incubated with propidium iodide (PI) solution. 
The cell suspensions were then transferred to fluorescence-
activated cell sorting tubes and analyzed using a Coulter 
Epics XL instrument.
UM-scc-47 cellular uptake studies
UM-SCC-47 cells were seeded in 24-well plates at a density 
of 50,000 cells per well, and cultured in RPMI-1640. 
At near confluency, the medium was removed, and the cells 
were washed twice with PBS. Cells were then exposed to 
PLGA NPs labeled with RhB at a concentration of 10 µM 
in growth medium for 24 h. After 24 h of incubation, the 
cells were washed twice with PBS, detached using trypsin–
EDTA, and the amount of label associated with the cells was 
assayed by fluorescence measurements (λ excitation: 553 nm, 
λ emission: 627 nm).
The uptake of NPs by the UM-SCC-47 cells was also 
examined by confocal microscopy. UM-SCC-47 cells were 
seeded on glass coverslips in 24-well plates, 50,000 cells 
per well. When cells reached 70% confluency, they were 
treated with CDDP-loaded NPs that were labeled with RhB 
for 24 h. The cells were then fixed with 4% paraformalde-
hyde for 20 min at ambient temperature and washed twice 
with PBS and stained with phalloidin to visualize the actin 
cytoskeleton. Alternatively, for colocalization studies, the 
cells were washed with PBS and incubated with LysoTracker-
Green (New England Biolabs). Images were obtained using 
a BioRad radiance 2100 laser scanning confocal microscope 
equipped with green and red filters.
Results and discussion
characteristics of the NPs
Using a single-needle EHDA method, with a loading 
efficiency .70%, the mean diameter of NPs varied with 
the amount of loaded CDDP, as previously reported,21 and 
the higher CDDP loading of 10 wt% (U-CDDP) induced the 
smallest average diameter of 550±80 nm (Figure 1). An initial 
burst in release was observed within the first 4 h (14% of drug 
was released for 10 wt%), followed by a sustained release 
profile (Figure 2), indicating the potential of CDDP-loaded 
PLGA NPs as a controlled drug delivery system.
However, since the drug release profile plays a potentially 
crucial role in the efficacy of a chemotherapy treatment, we 
sought to further control this process by developing a coaxial 
needle EHDA methodology to produce a CS-type CDDP 
PLGA NP (Figure 3). As shown in Figure 1, novel CS-CDDP 
(CS-CDDP) NPs were produced with a smooth outer sur-
face and a mean diameter of 850±200 nm. Furthermore, 
high encapsulation efficiencies (.80%) were achieved in 
agreement with data for coaxial electrospraying of other 
chemotherapeutics.25 
The drug distribution within NPs potentially plays an 
important role in controlling delivery; therefore, we sought 
to examine the CDDP within the loaded NPs. FTIR spectra 
of PLGA NPs loaded with CDDP are shown in Figure S1. 
All the NPs showed characteristic PLGA peaks attribut-
able to C=O stretching (1,754 cm−1) and C–O stretching 
(1,050–1,250 cm−1) and a weak peak for amine stretching 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
98
 o
n 
23
-J
un
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3917
electrohydrodynamic fabrication of core–shell cDDP-Plga nanoparticles
(3,294 cm−1), indicating the presence of intact drug (CDDP), 
in line with EDS spectra (Figure S2). Additionally, the ther-
mogram of the CDDP-loaded materials (Figure S3) did not 
show an exothermic peak at 281°C, observed for the drug 
alone, suggesting that the drug is molecularly dispersed in 
an amorphous form.26 Energy-dispersive X-ray spectroscopy 
(EDS) Pt mapping was used to evaluate the distribution of 
CDDP within both types of NPs. It can be seen that the drug 
is well distributed throughout the single-needle-derived 
U-CDDP NPs (Figure 4). In contrast, importantly, distribu-
tion of the drug in the coaxial needle-derived CS-CDDP par-
ticles is more localized to the core of the particles, concurrent 
with variation in intensity observed in the TEM micrographs, 
suggesting a CS structure (Figure 4A).
In vitro drug release characteristics
It can be seen in Figure 2 that a biphasic release profile 
was observed under physiological conditions for both 
the single-needle (U-CDDP) and the coaxial (CS-CDDP) 
formulations. Among the previously reported single-needle 
NP formulations with different quantities of CDDP, we 
selected 10 wt% of CDDP-loaded PLGA NPs for further in 
vitro and in vivo experiments, because these NPs showed 
a sufficiently high loading amount and the best sustained 
release (smallest burst release – 14%).21 
Figure 1 scanning electron microscope and corresponding size distribution graphs of (A) U-cDDP and (B) cs-cDDP nanoparticles produced by single- and coaxial needle 
EHDA configurations, respectively.
Abbreviations: U, uniform; cs, core–shell; cDDP, cisplatin; ehDa, electrohydrodynamic atomization.
?
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Figure 2 structure-dependent cDDP release.
Notes: Plga nanoparticles with U-cDDP and cs-cDDP loading were incubated 
in PBs at 37°c and ph 7.4. The data show the mean ± sD (n=3).
Abbreviations: Plga, poly(lactic-co-glycolic acid); U, uniform; cs, core–shell; 
cDDP, cisplatin; PBs, phosphate-buffered saline; sD, standard deviation.
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However, the CS-CDDP formulation demonstrated a 
shorter burst release period (~1 h), followed by a controlled 
zero-order (linear) release period. The higher linearity of 
the second release stage of the CS-CDDP NPs in compari-
son to the U-CDDP NPs can be explained by the different 
architecture of the CS-CDDP particles. The CS-CDDP NPs 
have a region of lower CDDP density around the perimeter 
of the particles. As expected, the CDDP release rate from the 
CS-CDDP NPs is slower than that of the U-CDDP NPs, due 
to the presence of the PLGA shell through which the drug 
is released. This structural feature is potentially favorable 
for controlled release of drug molecules at the tumor site, 
while serving as an inhibitor against leaking of the CDDP-
loaded NPs. This is consistent with previously reported CS 
structured particles produced by coaxial electrospraying 
that often exhibit a sustained drug release that is tunable by 
adjusting the shell material or thickness.25
The underlying processes in drug release from PLGA are 
quite complex,27 involving diffusion of water and drug and 
hydrolysis and structural modification of PLGA. It is known, 
however,28 that the timescale for significant degradation of 
PLGA in water, although composition-dependent, is at least 
a month. It is therefore reasonable to assume that the release 
rates in Figure 2 should be described, after the initial burst, 
by diffusion through material with a constant diffusion coef-
ficient. Analytical results for which are well known for a solid 
sphere and a spherical shell.28
The U-CDDP NP release in Figure 2 can be modeled 
by assuming a uniform distribution of CDDP in a PLGA 
matrix with a 550 nm diameter and a diffusion coefficient 
D = × − −4 1 10 21 2 1. m s . This was determined by choosing 
a value of D that gave the best fit to the release kinetics 
(a goodness-of-fit parameter R2 of 0.9795 was achieved), 
using the expression for release fraction ϕ from particles of 
radius a as a function of time t derived by Eltayeb et al:29
 
ϕ
π
( ) tanh
( )
t
Dt
a
= 


6 1 2
1 2
 
(2)
Since the polymer structure should be similar, we assume 
that the same value of D applies to the CS-CDDP NPs. 
The release rate from these particles is very nearly linear, 
????????????????
?
????????????????????
?????????????????????????
?????????????????????????????
??????????????????????????????
Figure 3 schematic of the experimental setup used to prepare cs-cDDP drug-loaded particles.
Abbreviations: cs, core–shell; cDDP, cisplatin; Plga, poly(lactic-co-glycolic acid).
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and according to the theory of spherical shell diffusion, 
the deviation from linear behavior involves a series of 
terms involving30,31
 
exp
( )
−
−




Dn t
b a
2
2
π
 
(3)
where t is the time, (b − a), the difference between the particle 
radius and the core radius, is the shell thickness, and n is an 
integer $1.
It is clear from the release kinetics in Figure 2 that any 
deviation from linear behavior occurs on a timescale ,2 h, 
requiring a shell thickness of 50 nm or less, consistent with 
observations made from TEM micrographs of this material 
(Figure 4). For small releases from the core, the fraction 
release in the linear regime is
 
ϕ ( )
( )
t
bDt
a b a P
=
−
3
2
 
(4)
where P is the partition coefficient for CDDP, giving the 
ratio of the concentration in the core to the concentration at 
the inner surface of the shell.
Using a shell thickness of 50 nm and particle diameter 
of 850 nm, fitting equation 4 to the near-linear part of the 
release rate at times in excess of 1 h gives a fractional release 
??????
?
??????????
??????
?
??????
?
??????????
??????
?
Figure 4 TEM bright-field micrographs of (A) cs-cDDP and (C) U-CDDP NPs and dark-field STEM micrographs of (B) cs-cDDP and (D) U-cDDP NPs with overlaid 
eDs Pt mapping (red).
Abbreviations: TeM, transmission electron microscope; cs, core–shell; U, uniform; cDDP, cisplatin; NPs, nanoparticles; sTeM, scanning transmission electron microscope; 
eDs, energy-dispersive X-ray spectroscopy; Pt, platinum.
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rate of 0.052% h−1 with an R2 value of 0.9. This leads to a 
partition coefficient of 5.2, comparable with the measured 
partition coefficient of CDDP between CH
2
Cl
2
 (a proxy for 
a lipid shell) and water, which was 16.3.32 PLGA is more 
hydrophilic than CH
2
Cl
2
, so it is reasonable that our parti-
tion coefficient is smaller. Therefore, we conclude that the 
release profiles shown in Figure 2 are consistent with simple 
diffusive release.
Characterizing the efficacy of NPs 
in vitro
Both the prepared drug delivery NPs are expected to act 
as an intracellular depot increasing CDDP efficacy. Rapid 
dissociation of the drug from NPs may result in premature 
release in the blood stream, significantly reducing the 
efficient delivery of the drug molecules to the desired tis-
sue/organ and increasing systemic toxicity, hence limiting 
dosage. Therefore, it is crucial to both control the delivery 
profile of drugs from NPs and evaluate its effect in promoting 
improved chemotherapy.
In vitro activity of cDDP-loaded NPs on squamous 
carcinoma cell line
The cytotoxic of free CDDP and CDDP-loaded PLGA NPs 
was evaluated in vitro by viability assay (MTT colorimetric 
assay), using a human head and neck squamous carcinoma 
UM-SCC-47 cell line, and results are expressed as % relative 
cell viability (Figure 5). The CDDP dosages were selected 
based upon the measured 50% maximal response (concen-
tration of a drug that gives half maximal response [EC
50
]) 
values for free CDDP.
As shown in Figure 5, blank PLGA NPs with 0 wt% 
CDDP loading exhibited negligible toxicity against UM-
SCC-47 cells at all time points, consistent with the high 
biocompatibility of this material.33 
When the UM-SCC-47 cells were exposed to the NPs 
loaded with CDDP for 24 h, the particles exhibited an in vitro 
anticancer activity similar to free drug at the same dosage. 
After 48 h, there was a large decrease in cell viability for both 
the NP groups (EC
50
 =8 and 7.4 µM for U-CDDP and CS-
CDDP, respectively), for example, this dropped from ~90% 
??
?
????????? ?????? ??????? ???
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Figure 5 In vitro cytotoxicity of different dosages (5–50 µM) of free cDDP, cDDP-Plga NPs, and equivalent non-drug-loaded NPs against UM-scc-47 cells after 
incubation for (A) 24 h, (B) 48 h, and (C) 72 h.
Note: The results represent the mean ± sD (n=6).
Abbreviations: Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles; sD, standard deviation; U, uniform; cs, core–shell; cDDP, cisplatin.
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6.2 µM for U-CDDP and CS-CDDP, respectively; Figure 6) 
compared to 70% and 45% for doses of 10 and 20 µM free 
CDDP, respectively (EC
50
 =9.0 µM), indicating potential 
enhancement in anticancer activity from the NP formulations. 
Furthermore, it is interesting to note that at the 72-h time 
point, only ~35% and 20% of the CDDP is released from the 
U-CDDP and CS-CDDP NPs, respectively (Figure 2).
The temporal viability of UM-SCC-47 cells was also 
observed by staining live and dead cells with calcein-AM 
and ethidium homodimer-1, respectively. Consistent with 
MTT results, there is a dramatic reduction in the number 
of live (viable) cells after 72 h treatment with both the free 
drug and CDDP-loaded NP formulations, in contrast to the 
control group that exhibited cell growth (Figure 7). This cell 
killing was highest after 48 h and is particularly marked for 
the NP groups, concurrent with the increased anticancer 
efficacy observed in the MTT experiments. Assuming the 
release of CDDP plays the crucial role in cytotoxicity of 
the CDDP-PLGA particles, this indicates that both types of 
NPs enhance the anticancer efficacy of CDDP, consistent 
with a sustained release profile that potentially achieves a 
??
?
?
?
?
????
?? ?
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????
??????????????????????
Figure 6 ec50 values for free cDDP and cDDP-Plga NPs after incubation for 
48 h and 72 h.
Note: The results represent the mean ± sD (n=6).
Abbreviations: Plga, poly(lactic-co-glycolic acid); NPs, nanoparticles; sD, standard 
deviation; U, uniform; cs, core–shell; cDDP, cisplatin; ec50, concentration of a drug 
that gives half-maximal response.
???? ???? ????
???
????
???
????
??
???
???
???
???
????
???
???
???
?
???
???
????
???
Figure 7 live/dead cell staining for UM-scc-47 cells with treatment of media (control), U-cDDP NPs (10 µM), and cs-cDDP NPs (10 µM).
Note: live cells were stained green with calcein-aM and dead cells were stained red with ethidium homodimer-1.
Abbreviations: U, uniform; NPs, nanoparticles; cs, core–shell; cDDP, cisplatin.
at 24 h to 50% at 48 h for the 10 µM dosage. Similarly, the 
EC
50
 for the free drug at 48 h dropped to 7.1 µM. Importantly, 
the UM-SCC-47 cells exposed to 10 µM CDDP NPs for 72 h 
displayed a further drop in viability to ~40% (EC
50
 =7.6 and 
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metronomic dosing effect (equally spaced administration of 
lower doses of chemotherapeutic drugs without extended rest 
periods). This treatment has shown potential for increased 
antitumor efficacy with very low toxicity.34
To further evaluate anticancer efficacy and the mecha-
nism of cell death, we labeled the treated and non-treated 
cells with FITC-labeled Annexin V, which binds to phos-
phatidylserine exposed on the outside of the cell membrane 
in apoptotic cells. The cells were counterstained with PI that 
labels the nucleus of late apoptotic and necrotic cells. As 
seen in Figure 8, treatment with both CDDP-loaded NPs and 
free CDDP induces comparable apoptosis of the tumor cells. 
After 48 h, there was an increase in necrosis and apoptosis 
for both the free drug and NP treatments. The increase was 
slightly greater for the U-CDDP NP treatment, from ~10% 
apoptosis (24 h) to 27% (48 h), compared to 22% and 20% 
(48 h) for free drug and CS-CDDP, respectively. Interest-
ingly, the necrosis level was also highest for the U-CDDP 
NPs, which could be due to the greater rate of CDDP release 
by the NPs with uniform CDDP distribution (U-CDDP) 
compared with the CS-CDDP formulation (Figure 8). There 
was a small further increase in apoptosis to ~34%, 39%, and 
30% for free, U-CDDP, and CS-CDDP encapsulated CDDP, 
respectively, at the 72-h time point, correlating with results 
from cell viability studies (Figures 5–7). Therefore, treat-
ment with the synthesized CDDP-loaded NPs can effectively 
induce apoptotic cell death, implying that the cytotoxicity 
of the drug-loaded particles is due to a sustained delivery of 
active CDDP. Furthermore, the dosage and hence the delivery 
period of CDDP are important in controlling cell death.
characterizing the uptake of NPs in vitro
To evaluate uptake into tumor cells, we labeled the NPs by 
complexing PLGA with RhB. After 24 h incubation with 
10 µM equivalent of CDDP-loaded NPs, UM-SCC-47 
cells demonstrated similar fluorescence intensity using a 
fluorimeter for both the CS-CDDP and the U-CDDP NPs, 
indicating no significant differences in internalization between 
the 2 particle architectures. This is in agreement with particle 
characterizations (Figures 1, 4, and S1), which revealed their 
relatively similar chemical composition and size.
Visual evidence of NP uptake by the UM-SCC-47 cells 
was also obtained by confocal microscopy, after incubation 
for 24 h. As shown in Figure 9, significant internalization 
?????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
???????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
??
??
??
????
??
??
???
????
????
?
????????
???????????
?
?????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
???????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
??
??
??
????
??
??
???
????
????
?
????????
?????????
??
?
?????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
???????
??
?????
??????
?????
?
????
?????
????
?
????
????
?????
??
??
??
????
??
??
???
????
????
?
????????
?????????
??
?
?
?
?
Figure 8 Facs data showing percentage of cells at each stage of death following different treatments measured at 24 h (A), 48 h (B), and 72 h (C) time points.
Abbreviations: FACS, fluorescence-activated cell sorting; U, uniform; CS, core–shell; CDDP, cisplatin.
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was observed as intense fluorescence (red) of NPs inside the 
cytoplasm of the cells. In control experiments with non-RhB-
labeled particles, no fluorescence was observed.
The particle internalization was further evaluated by 
co-labeling the cells with a LysoTracker-Green dye to 
identify the endolysosomal compartments. As shown in 
Figure 10, NPs appear to be internalized into endolysosomal 
compartments. It has been suggested that internalization of 
CDDP-loaded carriers is a key factor in increasing the drug’s 
efficacy.35,36 Therefore, the enhanced cytotoxicity of the 
PLGA nanocarriers in comparison to free drug may also be 
explained by the effective endocytosis exhibited by both types 
of NPs. The CS-CDDP NPs demonstrated relatively similar 
cytotoxicity to the U-CDDP NPs, although they released 
~10% less drug over the 72 h period, possibly, because they 
released less of the drug into the cell medium and more intra-
cellularly. Clearly, a combination of controlled release and 
efficient cellular uptake is required to increase the efficacy of 
this chemotherapeutic. Importantly, reducing the proportion 
of CDDP delivered prematurely is also crucial for reducing 
systemic toxicity associated with this drug in vivo.
Conclusion
We have demonstrated that the architecture of drug-loaded NPs 
can be engineered using rational design of an electrohydrody-
namic system, which improves anticancer efficacy of CDDP. 
Novel CS NPs demonstrated a shorter burst release and slower 
controlled release of CDDP, yet achieved similar cancer cell 
cytotoxicity to the uniform CDDP-distributed particles, which 
was also greater than free drug. Having shown the potential 
for increasing the maximal tolerated dose of this potent and 
widely employed, yet highly nephrotoxic, chemotherapeutic 
agent in vitro, these findings will be further confirmed with 
additional cell lines and by future in vivo experiments. The 
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Figure 9 (A and B) confocal microscope images and (C) TeM micrograph of UM-scc-47 cells after interaction with (A and C) U-cDDP and (B) cs-cDDP NPs. (D) 
Cellular uptake expressed as mean fluorescence intensity.
Note: Particles were functionalized with rhodamine B. red squares indicate the location of particles within the cell (C).
Abbreviations: aU, arbitrary unit; TeM, transmission electron microscope; U, uniform; cs, core–shell; cDDP, cisplatin; NPs, nanoparticles; Plga, poly(lactic-co-glycolic 
acid).
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Figure 10 confocal images showing examples of typical uptake of rhB-labeled Plga NPs (red).
Notes: The cells were counterstained with lysoTracker-green (green) to highlight endolysosomal compartments; colocalization of the signals shows internalization of the 
NPs into the endolysosomal compartments.
Abbreviations: rhB, rhodamine B; Plga, poly(lactic-co-glycolic acid); NP, nanoparticle; U, uniform; cs, core–shell; cDDP, cisplatin.
ubiquitous clinical use of CDDP, and widely demonstrated 
biocompatibility of PLGA, should facilitate translation of 
this technology and indicates that architecturally engineered 
delivery systems of this type should serve as an effective 
platform for successful cancer therapy.
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Figure S1 FTIr spectra of (A) cDDP, (B) U-cDDP, (C) cs-cDDP, and (D) Plga.
Abbreviations: aU, arbitrary unit; FTIr, Fourier transform infrared; U, uniform; cs, core–shell; cDDP, cisplatin; Plga, poly(lactic-co-glycolic acid).
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Figure S3 Dsc thermogram of (A) cDDP, (B) U-cDDP, (C) cs-cDDP, and (D) Plga.
Note: endotherms are indicated as peaks.
Abbreviations: Dsc, differential scanning calorimetry; U, uniform; cs, core–shell; cDDP, cisplatin; Plga, poly(lactic-co-glycolic acid).
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Figure S2 Typical eDs spectra of cDDP region of cs-cDDP NPs.
Abbreviations: eDs, energy-dispersive X-ray spectroscopy; cs, core–shell; cDDP, cisplatin; NPs, nanoparticles; at%, atomic percent (the percentage of one kind of atom 
relative to the total number of atoms).
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